Expression of Growth Hormone Receptors by Lymphocyte Subpopulations in the Human Tonsil

OLIVIER THELLIN, BERNARD COUMANS, WILLY ZORZI, ROSS BARNARD, GEORGES HENNEN, ERNST HEINEN and AHMED IGOUT

Institute of Human Histology; Laboratory of Biochemistry/Endocrinology, University of Liège, Belgium; Department of Physiology and Pharmacology, University of Queensland, Australia

(Received 7 August 1996; In final form 9 July 1997; Accepted 10 August 1997)

The ability of human tonsillar lymphoid cells to express growth hormone receptor (hGH-N-R) was analyzed by flow cytometry. FITC-coupled recombinant human growth hormone (hGH-N) was used to reveal the receptors, in combination with phenotype markers. Unlike T cells, tonsillar B cells constitutively express the hGH-N receptor. Quiescent cells separated from activated cells by Percoll-gradient centrifugation bear fewer receptors than activated ones. Activated T cells express hGH-N-R, but the typical germinal centre CD4+CD57+ T cells do not. These latter thus appear not to be fully activated.

Inside the lymph follicles, the germinal centre CD38+ B-cell population and the mantle-zone CD39+ B-cell population display similar levels of hGH-N-R expression, but receptor density is lower on dividing dark-zone CD38+CD10+ B cells.

Different lymphoid-cell populations thus differ markedly in their ability to express the growth hormone receptor, in relation notably to their activation status. This highlights the link between the neuroendocrine system and the active immune defense.

Keywords: Human growth hormone receptor, human tonsil, hGH-N, hGH-N-R, FACS, germinal center, lymph follicle

INTRODUCTION

Several studies have revealed two-way connections between the immune and the neuroendocrine systems (Mocchegiani et al., 1990; Murphy et al., 1992; Blalock, 1994; Clarke and Kendall, 1994; Mathison et al., 1994; Ottaway and Hurband, 1994; Fabris et al., 1995; Hooghe-Peters and Hooghe, 1995; Hooghe et al., 1996). This highly regulated ensemble forms a network of physiological reactions. Growth hormone produced by the pituitary, under the control of the hypothalamus, is one of the main actors in this network.

Growth hormone (hGH-N), in addition to its well-known metabolic effects, can modulate the immune system through its direct action on lymphocytes and their accessory cells. It is well established that human lymphoid cells express the growth hormone receptor...
(hGH-N-R) and even produce hGH-N (Kiess and Butenandt, 1985; Badolato et al., 1994; see for review Hooghe et al., 1996). The studies establishing these facts focused solely on crude lymphoid-cell populations, taking no account of the activation or maturation levels of subpopulations present.

Here we have examined expression of hGH-N-R by lymphocyte subpopulations freshly prepared from human tonsillar lymph follicles and by a mitogen-activated lymphocyte population. We have addressed the question: Does hGH-N-R expression by lymphocytes correlate with their activation or maturation status?

Different lymphocyte subpopulations were analyzed by flow cytometry. Mantle-zone B cells were studied by CD39 labeling, germinal center B cells by CD38 labeling, and dividing germinal center B cells by CD38*CD10+ labeling (Gregory et al., 1987; Liu et al., 1992; Hardie et al., 1993; Lagresle et al., 1993; MacLennan, 1994; Kremmidiotis and Zola, 1995; Lagresle et al., 1995; Dono et al., 1996). A peculiar population of T cells has been found inside the germinal centers; these cells are CD4+, most of them are CD57+ (Velardi et al., 1986; Bouzahzah et al., 1996a). On the basis of CD57 expression, we purified them by MACS and analyzed their hGH-N-R expression. Activated cells were separated from quiescent ones by Percoll-gradient centrifugation.

Expression of hGH-N-R was revealed by two different means: with mAb263 (mouse anti-hGH-N-R) and with FITC-labeled hGH-N. Since both methods gave similar results (to be published), we present here the results obtained with hGH-N/FITC.

By double labeling (anti-CD/PE and hGH-N/FITC), we identified cell types and checked their hGH-N-R expression.

**MATERIAL AND METHODS**

**Antibodies**

Phycoerythrin (PE)-conjugated anti-CD3, anti-CD10, anti-CD19, and unconjugated anti-CD19 and anti-CD8 monoclonal antibodies were provided by DAKO (Denmark). Simultest anti-CD3/FITC/CD19/PE, anti-CD38/PE, and biotinylated anti-CD57 mAbs were purchased from Becton-Dickinson (Rutherford, NJ). Rabbit anti-human Ig coupled to polyacrylamide beads was produced by Biorad Laboratories (Richmond, VA) and used at 1/600 final dilution. Anti-CD39/PE mAb was provided by Pharmingen (USA) and streptavidin/PE by Boehringer Mannheim (Germany). OKT3 and OKT11 mAbs were kindly provided by Thierry de France (Lyon, France) and mAb263 was a gracious gift from Ross Barnard (Queensland, Australia).

**Isolation of T Cells**

Tonsils from 1 to 8-year-old children were surgically removed and carried to the laboratory at 4°C in a physiological solution containing 0.4% BSA (Sigma, USA). Lymphocyte populations were prepared by gently teasing the tonsils. Free cells were harvested and T cells were separated by rosetting using sheep red blood cells (SRBC), treated with 2-aminoethylthiouonium, on a Ficoll Paque gradient (Pharmacia, Sweden). CD3+ cells were selected by eliminating CD19 cells from the rosetted population (Bouzahzah et al., 1996b). For this, the cells were incubated with mouse anti-CD19 antibodies before rinsing and adding Dynabeads-coupled anti-mouse IgG (Dynal, Norway). Labeled B cells were eliminated in a magnetic field. The purity of the T cells usually exceeded 95%, as determined by cytofluorometry (FACScan, Becton-Dickinson, USA).

CD4+ lymphocytes were purified similarly with anti-CD19 and anti-CD8 mAbs and Dynabeads.

CD4+CD57+ T cells were prepared (Bouzahzah et al., 1995) by means of a magnetic cell sorter (MACS, Becton-Dickinson, USA): Briefly, CD4+ cells were incubated for 30 min at 4°C with anti-CD57 mAb, then rinsed and placed in contact with PE-conjugated avidin and biotinylated magnetic beads (Sanvertec, The Netherlands). The cells were transferred to a separation column in the magnetic field of a MACS apparatus. CD4+CD57− cells passed through the column, CD57+ cells were retained by the magnetic
field. The resulting CD57+ and CD57− cells preparations were respectively 90% and 95% pure.

Isolation of B Cells
Of the nonrosetted cells, around 90% were B cells (CD19+). The concentration of B cells was improved to 95% and 98% of total population by eliminating the contaminating T cells with OKT3 and OKT11 and then Dynabeads (Bouzahzah et al., 1995).

Percoll Gradients
Tonsillar cells were separated (Cleary et al., 1995) by density centrifugation into high- and low-density cells on a discontinuous 30/50/100 % Percoll (Pharmacia, Sweden) gradient (1100 × g; 12 min). High-density cells were collected at the 50/100 % interface, and low-density cells at the 30/50 % interface. To preserve isotonicity (1 × PBS), the Percoll was diluted in PBS. Thus, 100% Percoll is defined as commercially available pure Percoll diluted in 0.1 volume of 10 PBS; 50% Percoll is a 1/1 dilution of Percoll in 1 × PBS, and 30% Percoll is obtained by mixing 0.6 volume of Percoll with 1.4 volume of 1 × PBS.

Preparation of hGH-N/FITC
Recombinant human GH-N (Kabi, Sweden) was coupled (Badolato et al., 1994; Rapaport et al., 1995) to FITC (Sigma). This was done as follow: hGH-N (1 mg/ml) was dissolved in 0.1 M sodium bicarbonate buffer, pH 9–9.4. FITC (1 mg/ml) was dissolved in dimethylsulfoxide (DMSO, Sigma). A 250-μl FITC solution was added to the dissolved hGH-N in 30-μl aliquots dispensed at 15-sec intervals under constant stirring. The mixture was then incubated overnight in darkness at 4°C. Free FITC was removed by three rounds of dialysis against 1000 volume of sodium bicarbonate buffer solution. This was performed at 4°C in the dark.

The protein concentration and the fluorescein/protein ratio (F/P) were determined by optical densitometry at 280 nm (protein) and 492 nm (FITC).

Bovine serum albumin (1 mg/ml BSA, Sigma) was conjugated to FITC by the same protocol and used as a negative control.

Fluorescin Labeling
Binding of hGH-N/FITC was evaluated by incubating 10⁶ lymphocytes with 5 μg hGH-N/FITC or BSA/FITC in PBS, pH 7.4, for 1 hr at 4°C in the dark. BSA/FITC was used as a negative control. After 30 min, PE-conjugated mAbs (anti-CD3, -CD10, -CD19, -CD38, or -CD39) were added at the adequate dilution. The cells were then washed twice in 1 ml cold PBS, resuspended in 750 μl cold PBS, and analyzed with the FACScan.

RESULTS
Saturation Curve
To test the capacity of hGH-N/FITC to bind hGH-N receptors of living cells, we prepared tonsillar lymphoid cells, labeled them with anti-CD19/PE to stain B cells, and incubated them with increasing amounts of hGH-N/FITC before measuring the percentage of FITC-positive cells with the FACS. The results indicate that saturation level begins at approximately 5 μg/ml (Figure 1). BSA/FITC was used as a negative control (Rapaport et al., 1995). The binding specificity of hGH-N/FITC has previously been proven by blocking with unlabeled hGH (Igout et al., 1995). The subsequent experiments were performed with 5 μg hGH-N/FITC/ml, which enabled us to label a high percentage of hGHN-R while limiting non-specific binding.

Total B- and T-Cell Populations
Crude and cultured lymph-cell populations were double-labelled with hGH-N/FITC and anti-CD3/PE (for T lymphocytes) or anti-CD19/PE (for B lymphocytes) mAbs. The results (Table I and Figures 2 and 3) obtained from six tonsils show that practically no T cell express hGH-N-R whereas 60–95% of B cells express it. These percentages are underestimated,
since we used a nonsaturating concentration of hGH-N/FITC to stain the cells. Furthermore, experiments showed a strong rise in hGH-N-R expression by T cells when these cells were activated by culturing for 24 or 48 hours in DMEM/F-12 with phycohemagglutinin L (PHA-L; 2 µg/ml); hGH-N-R expression also increased, but to a lesser extent, in lipopolysaccharide-activated B cells (10 µg/ml lipopolysaccharide; same culture conditions) (data not shown). In the tonsil, most T cells thus appear not to express hGH-N-R, whereas nearly all B cells exhibit a basal expression level. To verify this pattern of hGH-N-R expression, we prepared and studied isolated tonsillar B- and T-cell subpopulations.

### T-Cell Subpopulations

We double-labeled subpopulations of T cells (CD4+, CD8+, or CD57+) in mixed B-, T-cell populations and purified CD3+ or CD4+CD57+ cells with hGH-N/FITC. The results (Table II and Figure 2) show that in all tonsillar T-cell subpopulations, even for the CD57+ subpopulation, less than 5% of the cell express hGH-N-R. No difference was seen between the CD4+ and CD8+ populations. Incubation of these cells with PHA-L enhanced their hGH-N-R expression (data to be published).

### B-Cell Subpopulations

Crude B-, T-cell populations or purified CD19+ B cells were double-labeled with hGH-N/FITC and with anti-CD10, anti-CD19, anti-CD38, or anti-CD39/PE mAbs (Figure 4). The Mann-Whitney test was not applicable to either preparations because the results varied considerably from tonsil to tonsil (six tonsils, α = 5%) (Table III and Figure 3). To analyze differences between cell subpopulations, we thus examined each tonsil separately. In all six tonsils, CD38+ and CD39+ cells were found systematically to express more hGH-N-R per cell than CD38−CD10+ cells. Since this is probably due to the proliferation status of

---

**TABLE I Expression of hGH-N-R by of Tonsillar B and T lymphocytes (%)**

<table>
<thead>
<tr>
<th>Tonsil no.</th>
<th>CD3+ cells</th>
<th>CD19+ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&lt;5</td>
<td>67</td>
</tr>
<tr>
<td>2 (rosetted cells)</td>
<td>&lt;5</td>
<td>63</td>
</tr>
<tr>
<td>3</td>
<td>&lt;5%</td>
<td>82</td>
</tr>
<tr>
<td>4</td>
<td>ND</td>
<td>77</td>
</tr>
<tr>
<td>5</td>
<td>ND</td>
<td>76</td>
</tr>
<tr>
<td>6</td>
<td>&lt;5</td>
<td>95</td>
</tr>
</tbody>
</table>

**FIGURE 1** Saturation curve; ordinate: percentages of cells having bound hGH-N/FITC; abscissa: concentration of hGH-N/FITC.
FIGURE 2 Percentages of T-cell subpopulations expressing hGH-N-R.
CD38$^+$CD10$^+$ cells, we investigated hGH-N-R expression among high-density (nonactivated) and low-density (activated) tonsillar B and T lymphoid cells, separated on Percoll gradients.

**T-Cell Gradients**

Unseparated lymph cells were centrifuged on Percoll gradients, yielding high-density (small, nonactivated) and low-density (large, activated) cells. Both populations were investigated by double-labeling with hGH-N/FITC and anti-CD3/PE, anti-CD4/PE, or anti-CD8/PE mAbs. The results (Table IV), highly variable between tonsils, constantly show that more low-density T cells express hGH-N-R than high-density T cells. The percentage of hGH-N-R positive cells is lower, nevertheless, among activated (low-density) T cells than in the corresponding low-density B-cell population.

**B-Cell Gradients**

Unseparated lymph cells were centrifuged on Percoll gradients, yielding high-density (small, nonactivated) and low-density (large, activated) cells. Both populations were investigated by double-labeling with hGH-N/FITC and anti-CD19/PE, anti-CD39/PE, or anti-CD38/PE mAbs. The results (Table IV), highly variable between tonsils, constantly show that more low-density T cells express hGH-N-R than high-density T cells. The percentage of hGH-N-R positive cells is lower, nevertheless, among activated (low-density) T cells than in the corresponding low-density B-cell population.

**FIGURE 3** Percentages of B-cell subpopulations expressing hGH-N-R.

![Histograms showing percentages of B-cell subpopulations expressing hGH-N-R.](image)
TABLE II Expression of hGH-N-R by Tonsillar T-Cell Subpopulations (%)

<table>
<thead>
<tr>
<th>Tonsil no.</th>
<th>CD4+ cells</th>
<th>CD8+ cells</th>
<th>CD4+CD57+ cells</th>
<th>CD4+CD57+ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (rosetted cells)</td>
<td>ND</td>
<td>ND</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>2</td>
<td>ND</td>
<td>ND</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>3</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>4</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>5</td>
<td>ND</td>
<td>ND</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
</tbody>
</table>

N/FITC and anti-CD10/PE, anti-CD19/PE, anti-CD38/PE, or anti-CD39/PE mAbs. The results (Table V and Figure 5) show that low-density B cells express slightly more hGHN-R than high-density B cells and also more than the total B-cell population prior to separation. The hGH-N-R density varies on low-density B cells according to cell type: CD10+ cells express less hGHN-R than other cell types. Here again, high variability between tonsils is apparent, but the results for each tonsil show a higher percentage of labeled cells in the low-density population. In both the high- and low-density populations, fewer CD38+CD10+ cells than CD38+CD10- or CD39+ cell express the receptor.

DISCUSSION

Germinal centers develop in the secondary follicles of lymphoid organs by B-cell proliferation during a T-cell-dependent antibody response (MacLennan et al., 1992; MacLennan, 1994). Each germinal center is divided into a dark and a light zone. Centroblasts proliferate in the dark zone, and, migrating to the light zone, mature in contact with antigen-presenting follicular dendritic cells (FDC). During their maturation, CD38+CD10+ B cells first lose CD10, then CD38 at the end of maturation (Kremmidiotis and Zola, 1995), and finally CD39+ after maturation has finished (Lagresle et al., 1993).

![FIGURE 4 Schematic representation of a secondary lymph follicle in relation to a B-cell phenotype.](image-url)
Kiess and Butenandt (1985) have detected hGH-N-R on mononuclear cells from peripheral venous blood. Here we have investigated the capacity of subpopulations of tonsillar B and T lymphocytes to express hGH-N-R. Using fluorescein-labeled human growth hormone, cytometry, and cell-selection procedures, we have obtained new data on hGH-N-R. Unlike tonsillar T cells, tonsillar B cells constitutively express these receptors. T cells do so transiently when activated. Interestingly, the peculiar CD4+/CD57+ germinal center T cells do not express hGH-N-R. This confirms data from other authors, indicating that these cells are only in a preactivated state (Bouzahzah et al., 1995).

Among the follicular B cells, the dark-zone CD38+/CD10+ B cells possess few hGH-N-R. Perhaps proliferation causes B cells to reduce the density of hGH-N-R on their surface: During proliferation, activated cells express less hGH-N-R.

These differences between B and T cells and between resting and proliferating cells were observed on both mixed (crude) and purified lymphoid-cell populations and after centrifugation in Percoll. The results are confirmed by in vitro studies on mitogen-activated lymphoid cells (in preparation). Contamination by other cells bearing the CD of interest does not appear significant, since most of our data were obtained on highly purified B- or T-lymphocyte populations.

Since lymphocyte activation requires antigen recognition and costimulatory signals given by accessory or lymphoid cells, we can now hypothesize that activated cells bear higher numbers of certain receptors rendering them particularly receptive to messages, such as growth hormone, from the neuroendocrine system. Quiescent B cells appear more sensitive to growth hormone signaling than T cells, but activation opens the latter to the influence of growth

---

**TABLE III** Expression of hGH-N-R by tonsillar B cell subpopulations (%)

<table>
<thead>
<tr>
<th>Tonsil no.</th>
<th>CD38+ cells</th>
<th>CD38+CD10+ cells</th>
<th>CD39+ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>64</td>
<td>59</td>
<td>72</td>
</tr>
<tr>
<td>2 (rosetted cells)</td>
<td>72</td>
<td>63</td>
<td>65</td>
</tr>
<tr>
<td>3</td>
<td>87</td>
<td>62</td>
<td>84</td>
</tr>
<tr>
<td>4</td>
<td>86</td>
<td>68</td>
<td>75</td>
</tr>
<tr>
<td>5</td>
<td>ND</td>
<td>70</td>
<td>ND</td>
</tr>
<tr>
<td>6</td>
<td>ND</td>
<td>87</td>
<td>89</td>
</tr>
</tbody>
</table>

**TABLE IV** Expression of hGH-N-R by Quiescent (High-Density) or Activated (Low-Density) T Cells

<table>
<thead>
<tr>
<th>Tonsil no.</th>
<th>CD3+</th>
<th>CD4+</th>
<th>CD8+</th>
<th>CD3+</th>
<th>CD4+</th>
<th>CD8+</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&lt;5</td>
<td>ND</td>
<td>ND</td>
<td>12</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>69</td>
<td>75</td>
<td>75</td>
</tr>
<tr>
<td>3</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>25</td>
<td>22</td>
<td>26</td>
</tr>
</tbody>
</table>

**TABLE V** Expression of hGH-N-R by Quiescent (High-Density) or Activated (Low-Density) B Cells (%)

<table>
<thead>
<tr>
<th>Tonsil no.</th>
<th>CD19+</th>
<th>CD10+</th>
<th>CD38+</th>
<th>CD39+</th>
<th>CD19+</th>
<th>CD10+</th>
<th>CD38+</th>
<th>CD39+</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>70</td>
<td>55</td>
<td>60</td>
<td>70</td>
<td>83</td>
<td>81</td>
<td>83</td>
<td>82</td>
</tr>
<tr>
<td>2</td>
<td>73</td>
<td>53</td>
<td>60</td>
<td>57</td>
<td>82</td>
<td>76</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>3</td>
<td>92</td>
<td>90</td>
<td>85</td>
<td>85</td>
<td>95</td>
<td>92</td>
<td>97</td>
<td>95</td>
</tr>
<tr>
<td>4</td>
<td>91</td>
<td>89</td>
<td>93</td>
<td>92</td>
<td>95</td>
<td>91</td>
<td>97</td>
<td>96</td>
</tr>
</tbody>
</table>
FIGURE 5  Percentages of high- and low-density B-cell subpopulations expressing hGH-N-R.
hormone. The sensitivity of the immune system to signals of the neuroendocrine system thus depends on its stimulation level.

These observations reinforce the view that hGH-N is part of the immune system regulation machinery.

Acknowledgments

The authors thank M. Jackers and A. M. Greimers for excellent technical assistance. This work was supported by the Convention Région Wallonne, Université de Liège 2640.

References


